Tom Okarma working for BTX was working for Geron

Dr West is CEO of BioTime and was the founder of Geron. Tom Okarma was hired by Dr. West who also worked at Geron and was a leader in the embryonic movement. Was Geron sell [more like give it to BioTime] it to Dr. West. Maybe. If I remember what I read GE has the right to review any deal and make a deal with Geron. Geron closed down 0.055 cents at $1.38. The volume was low only 452,103 shares ..................................................................................................................................... ..................................................................................................................................................................................................................................................................... ACTC closed down a little at 0.0715. I think we go under 6 maybe by Dec................ ..............................................................................................................................................................................AAPL up big to close at $634.03, need $40 more for my calls. The iPod mini Tue. and earnings Thur.......................................................................... ..............................................................................................................................................................................Good luck in this rigged casino,

ACTC Clinical Trial Advances

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its European clinical trial for Stargardt’s Macular Dystrophy (SMD). The patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with 50,000 cells in the three patients comprising the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully. “Our progress continues in our European clinical trial and both our trials in the U.S., as seen most recently with last week’s announcement of treatment of the second patient in the second patient cohort of our U.S. trial for SMD,” said Gary Rabin, chairman and CEO of ACT. “As I mentioned last week, we have mapped out the series of patients to complete the second cohort of both our trials for SMD, as well as for our trial for dry age-related macular degeneration (dry AMD), pending DSMB review, and we anticipate generating patient data at a faster pace.” Initiated in January of this year, the Phase I/II trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study’s primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. The company is concurrently conducting another trial for SMD and one for dry AMD, both in the U.S. “We are very gratified to be initiating the first treatment of the second patient cohort in our European clinical trial, having just started it this year,” commented Robert Lanza, M.D., ACT’s chief scientific officer. “Our two U.S. trials also continue to move steadily forward.” Further information about patient eligibility for ACT’s SMD study and the concurrent studies in the U.S. and Europe (for dry age-related macular degeneration and SMD, respectively) are available at www.clinicaltrials.gov, with the following Identifiers: NCT01469832 (E.U. SMD), NCT01345006 (U.S. SMD), and NCT01344993 (dry AMD). About Stargardt’s Disease Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration........................................................ ..................................................................................................................................................................................................................................................................... Good news, I hope the results are great. This would be great news for all the stem cell companies and the science....................................................... ..................................................................................... Good luck in this rigged casino,

It's a Small World for Geron

I was reading about BioTime and found Dr. Michael West is CEO of BioTime. Dr. West was also the founder of Geron 20+ years ago. He left Geron a few years back. Now Dr. West wants to buy his baby back, nice. Also BioTime uses ACTCellerate technology, yea ACTC what a small world. I'm thinking there's a game being played here and the shareholders are not in on it...................................................................... .............................................................................................................................................................................. Good luck in this rigged casino,

Geron, ACTC, AAPL all down

AAPL is killing me, closed at $609.84. I need blowout earnings Oct 25th, a $65 run up for my calls to make money. ....................................................................................... ACTC down again at 0.0733. With no news we go lower. ...................................................................................... Geron closed at $1.44 down we go. The BXT offer is better than nothing, but it's close to nothing. I'll vote for it.......................................................... ....................................................................................... Good luck in this rigged casino,

Great News for Stem Cell Believers

9:05AM Geron: BioTime (BTX) issues open letter to shareholders of Geron; proposes transaction between Biotime Acquisition and Geron (GERN) 1.42 : BioTime (BTX) issued a letter to the shareholders of Geron regarding Geron's stem cell assets. BTX proposes Geron shareholders could own up to 45% of a new publicly traded co that will own the Geron stem cell assets, $40 mln of BioTime stock, certain BioTime stem cell assets, and shares of certain BioTime stem cell subsidiaries. Geron shareholders would also receive BioTime stock-purchase warrants presently valued at ~$13 mln. Geron would retain its cancer therapy business, including Imetelstat and GRN1005, and its cash and short-term liquid investments and Geron shareholders would continue to own 100% of the Geron cancer therapy business through their ownership of Geron stock. Through the "Stem Cell Transaction", Geron would transfer its stem cell assets to BioTime Acq, in exchange for which you along with the other Geron shareholders would receive shares of BAC common stock representing ~21.4% of the outstanding BAC capital stock. BioTime would contribute to BAC the following assets in exchange for the balance of outstanding BAC capital stock: $40 mln in BioTime common shares; Warrants to purchase BioTime common shares; Rights to certain stem cell assets of BioTime, and shares of two BioTime subsidiaries engaged in the development of therapeutic products from stem cells. .............................................................................................................................................................................................................................................................. This is all Geron is going to get. I'm going to take it. I believe in the science. I hope BioTime restarts the Phase 1 trials on spinal injuries soon. Just hope I live long enough to see results. Geron is up over $1.51. BTX was up a penny................ Good luck in this rigged casino,

I Stopped Waiting AAPL up big

AAPL up big on the news of Ipod mini, closed at $649.79 up $15.03 on 19.5 million shares. The three month avg. volume 15.8 million shares. Need $30 more for my calls. . . . Geron is going no where fast closing again at $1.37 shares. The volume only 339,014 shares. No market interest, need good news or we go lower. . . . ACTC down again at 0.0725 on 3.7 million shares. The three month avg. volume is 5.7 million shares. Need more good news on the Phase 1/2 trials or we will go lower.. . . . Good luck in this rigged casino,

Still Waiting Geron, ACTC and AAPL

AAPL should start it's run up into earnings Oct 25th. Closed up $5.05 at $634.76. Need $40s to made money on my 3 calls...................................................... ......................................................................................................................................................................................................................................................................ACTC down just a little at 0.0735. Need news soon if not we go lower. ......................................................................................................................................................................................................................................................................Geron closed flat at $1.37, volume was only 264,971. Needs news soon or we go under $1.............................................................................................................................................................................Good luck in thiis rigged casino,